awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q35050210-FB1BC7DB-87CE-49D2-8301-01D217743AA2
Q35050210-FB1BC7DB-87CE-49D2-8301-01D217743AA2
BestRank
Statement
http://www.wikidata.org/entity/statement/Q35050210-FB1BC7DB-87CE-49D2-8301-01D217743AA2
Rationale for targeting VEGF, FGF, and PDGF for the treatment of NSCLC
P2860
Q35050210-FB1BC7DB-87CE-49D2-8301-01D217743AA2
BestRank
Statement
http://www.wikidata.org/entity/statement/Q35050210-FB1BC7DB-87CE-49D2-8301-01D217743AA2
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
cda5ef626ea2b08148c46cd39450ff968bf9a709
P2860
Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426.